PURPOSE: To verify the effectiveness of percutaneous @entity1068 injection ( @entity8681 ) in the treatment of large (>30-mL) hyperfunctioning thyroid nodules. MATERIALS AND METHODS: Twelve @entity1 (eight @entity1 , four @entity1 ; age range, 26-76 years) with a large hyperfunctioning thyroid nodule (volume range, 33-90 mL; mean, 46.08 mL) underwent @entity8681 treatment under ultrasonographic (US) guidance. US was used to calculate the volume of the nodules and to assess the diffusion of the @entity1068 in the lesions during the procedure. When incomplete @entity39 of the nodule was depicted at scintigraphy performed 3 months after treatment, additional @entity8681 sessions were performed. RESULTS: Four to 11 @entity8681 sessions (mean, seven) were performed in each @entity1 , with an injection of 3-14 mL of 99.8% @entity1068 per session (total amount of @entity1068 per @entity1 , 30-108 mL; mean, 48.5 mL). At scintigraphy after treatment in all @entity1 , recovery of extranodular uptake, absence of uptake in the nodule, and normalization of thyroid-stimulating hormone (thyrotropin) levels were observed. In all @entity1 , US showed volume reductions of 30%-50% after 3 months and 40%-80% after 6-9 months. Side effects were self-limiting in all @entity1 . During the 6-48-month follow-up, no recurrence was observed. CONCLUSION: @entity8681 is an effective and safe technique for the treatment of large hyperfunctioning thyroid nodules.

Percutaneous XXXX injection of large autonomous hyperfunctioning thyroid nodules.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol'] @entity8681 :: ('CHEBI:53231', 'Chemical') :: ['PEI'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']
@entity1068 :: (MESH:D000431,Chemical) :: ['ethanol']
